Copyright syracuse.com
A commonly prescribed medication for attention-deficit hyperactivity disorder (ADHD) has been recalled nationwide after failing to meet dissolution standards during laboratory testing. According to an enforcement report from the Food and Drug Administration (FDA), Sun Pharmaceutical Industries Inc. initiated a voluntary recall on Oct. 28 for its lisdexamfetamine dimesylate capsules, a generic alternative to the brand-name drug Vyvanse. The recall affects multiple dosage strengths of the stimulant medication, which is prescribed to improve focus in patients with ADHD. It can also be prescribed to treat Binge Eating Disorder (BED), per the FDA. The FDA classified the action as a Class II recall on Oct. 30, indicating the medication could cause temporary or medically reversible health problems. The report also notes that affected lisdexamfetamine dimesylate capsules failed to dissolve properly during testing, but no specific details about the failure were provided. The recall includes 100-count bottles in seven dosage strengths ranging from 10 mg to 70 mg. Each strength has multiple lot numbers with expiration dates between February 2026 and May 2026. Patients can identify affected bottles by checking the lot numbers printed on their medication packaging. The lots affected are as follows: Lisdexamfetamine Dimesylate Capsules, 10 mg - 100-count bottle AD42468 (Exp. Date 2/28/26) AD48705 (Exp. Date 4/30/26) Lisdexamfetamine Dimesylate Capsules, 20 mg - 100-count bottle AD42469 (Exp. Date 2/28/26) AD48707 (Exp. Date 4/30/26) Lisdexamfetamine Dimesylate Capsules, 30 mg - 100-count bottle AD42470 (Exp. Date 2/28/26) AD48708 (Exp. Date 4/30/26) Lisdexamfetamine Dimesylate Capsules, 40 mg - 100-count bottle AD48709 (Exp. Date 4/30/26) AD50894 (Exp. Date 5/31/26) Lisdexamfetamine Dimesylate Capsules, 50 mg - 100-count bottle AD48710 (Exp. Date 4/30/26) AD50895 (Exp. Date 5/31/26) Lisdexamfetamine Dimesylate Capsules, 60 mg - 100-count bottle AD48711 (Exp. Date 4/30/26) AD50896 (Exp. Date 5/31/26) Lisdexamfetamine Dimesylate Capsules, 70 mg - 100-count bottle AD48712 (Exp. Date 4/30/26) AD50898(Exp. Date 5/31/26) The FDA has not issued any specific instructions for patients who possess the recalled medication. If you have any bottles affected by the recall, contact your pharmacy or doctor for guidance on next steps.
